Literature DB >> 17213270

Conservative treatment for patent ductus arteriosus in the preterm.

Sophie Vanhaesebrouck1, Inge Zonnenberg, Piet Vandervoort, Els Bruneel, Marie-Rose Van Hoestenberghe, Claire Theyskens.   

Abstract

BACKGROUND: A patent ductus arteriosus (PDA) is common among preterms, and prophylactic medical treatment has been advocated as the first-line approach. Conservative treatment may result in similar outcome, but without exposure to the harmful side effects of medication. A retrospective analysis revealed a ductal closure rate of 94% after conservative treatment with adjustment of ventilation (lowering the inspiratory time and increasing positive end expiratory pressure) and fluid restriction.
OBJECTIVE: To study prospectively over one year the rate of PDA closure, and morbidity and mortality following conservative treatment.
METHOD: Prospective study (1 January 2005 - 31 December 2005) including 30 newborns <or=30 weeks' gestation, all of whom were being ventilated and required surfactant. Echocardiography was performed 48-72 h after birth. Clinically important PDA was conservatively treated as described above. The percentage of children with PDA, ductal ligation and major complications was determined.
RESULTS: Ten neonates (33%) developed a clinical important PDA. Following conservative treatment the duct closed in all neonates (100%), and none required ductal ligation or medical treatment. The rates of major complications were no higher than those reported by the Vermont Oxford Network and in the literature.
CONCLUSION: The managed care plan resulted in an overall ductal closure rate of 100%. These results suggest that conservative treatment of PDA is a worthy alternative to prophylactic medical treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213270      PMCID: PMC2675417          DOI: 10.1136/adc.2006.104596

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  25 in total

1.  Primum non nocere: prophylactic versus curative ibuprofen.

Authors:  Cathy Hammerman; Michael Kaplan
Journal:  Lancet       Date:  2004 Nov 27-Dec 3       Impact factor: 79.321

2.  Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment.

Authors:  P S Koehne; G Bein; V Alexi-Meskhishvili; Y Weng; C Bührer; M Obladen
Journal:  J Perinat Med       Date:  2001       Impact factor: 1.901

3.  Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.

Authors:  F Mosca; M Bray; M Lattanzio; M Fumagalli; C Tosetto
Journal:  J Pediatr       Date:  1997-10       Impact factor: 4.406

Review 4.  Surgical versus medical treatment with cyclooxygenase inhibitors for symptomatic patent ductus arteriosus in preterm infants.

Authors:  M Malviya; A Ohlsson; S Shah
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 5.  Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.

Authors:  P W Fowlie; P G Davis
Journal:  Cochrane Database Syst Rev       Date:  2002

6.  Ibuprofen: alternative treatment for patent ductus arteriosus.

Authors:  Melissa Flores
Journal:  Neonatal Netw       Date:  2003 Mar-Apr

7.  Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.

Authors:  A Varvarigou; C L Bardin; K Beharry; S Chemtob; A Papageorgiou; J V Aranda
Journal:  JAMA       Date:  1996-02-21       Impact factor: 56.272

Review 8.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  S S Shah; A Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 9.  Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  A Ohlsson; R Walia; S Shah
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 10.  Indomethacin for asymptomatic patent ductus arteriosus in preterm infants.

Authors:  L Cooke; P Steer; P Woodgate
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  27 in total

1.  The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment.

Authors:  Jeff Reese; Matthew M Laughon
Journal:  J Pediatr       Date:  2015-08-24       Impact factor: 4.406

2.  Therapeutic strategies, including a high surgical ligation rate, for patent ductus arteriosus closure in extremely premature infants in a North American centre.

Authors:  Gregory P Moore; Sarah L Lawrence; Gyaandeo Maharajh; Amanda Sumner; Isabelle Gaboury; Nick Barrowman; Brigitte Lemyre
Journal:  Paediatr Child Health       Date:  2012-04       Impact factor: 2.253

3.  Serial N-terminal pro-brain natriuretic peptide measurement as a predictor of significant patent ductus arteriosus in preterm infants beyond the first week of life.

Authors:  Johannes Buca Letshwiti; Jan Sirc; Ruth O'Kelly; Jan Miletin
Journal:  Eur J Pediatr       Date:  2014-06-05       Impact factor: 3.183

4.  Serial echocardiography in very preterm infants: a pilot randomized trial.

Authors:  Sara B DeMauro; Meryl S Cohen; Sarah J Ratcliffe; Soraya Abbasi; Barbara Schmidt
Journal:  Acta Paediatr       Date:  2013-09-13       Impact factor: 2.299

5.  A randomized trial of intravenous acetaminophen versus indomethacin for treatment of hemodynamically significant PDAs in VLBW infants.

Authors:  J M Davidson; J Ferguson; E Ivey; R Philip; M F Weems; A J Talati
Journal:  J Perinatol       Date:  2020-05-21       Impact factor: 2.521

6.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 7.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

8.  Surgical Ligation Versus Percutaneous Closure of Patent Ductus Arteriosus in Very Low-Weight Preterm Infants: Which are the Real Benefits of the Percutaneous Approach?

Authors:  A Rodríguez Ogando; I Planelles Asensio; A Rodríguez Sánchez de la Blanca; F Ballesteros Tejerizo; M Sánchez Luna; J M Gil Jaurena; C Medrano López; J L Zunzunegui Martínez
Journal:  Pediatr Cardiol       Date:  2017-11-08       Impact factor: 1.655

9.  Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus.

Authors:  James I Hagadorn; Elizabeth A Brownell; Jennifer M Trzaski; Kendall R Johnson; Shabnam Lainwala; Brendan T Campbell; Katherine W Herbst
Journal:  Pediatr Res       Date:  2016-08-10       Impact factor: 3.756

Review 10.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.